Advertisement

Topics

Endocyte, Inc. Company Profile

00:42 EST 22nd November 2017 | BioPortfolio

Endocyte is a privately held biotechnology company with headquarters in the Purdue Research Park of West Lafayette, IN. Based on the applications of Endocyte’s advanced proprietary guided drug technology, the company is working to develop new drugs and diagnostic agents to treat many types of cancer and other serious diseases. The guided drug platform makes it possible to use highly potent drugs on extended and frequent dosing schedules and in combination with other drugs to maximize efficacy. The technology improves drug targeting and reduces the risk of side effects by combining drugs with ligands that are able to identify and attach to receptors found on tumor and other disease cells. Other clinical-stage products in the Endocyte pipeline include EC0225, a targeted combination of two potent anticancer drugs; EC0489, a targeted cancer drug; and EC17, a targeted immunotherapy agent.


News Articles [31 Associated News Articles listed on BioPortfolio]

Biotech Stocks on Investors' Radar -- Endocyte, Editas Medicine, Halozyme Therapeutics, and Illumina

http://dailystocktracker.com/register/ Endocyte On Friday, shares in West Lafayette, Indianaheadquartered Endocyte Inc. recorded a trading volume of 1.11 million shares. The stock ended the sessio...

Endocyte in-licenses Phase III-ready PSMA-targeted radioligand therapy

US biopharma firm Endocyte has executed an exclusive worldwide license of PSMA-617 from ABX GmbH.

Endocyte Adds Phase 3-Ready Prostate Cancer Drug with ABX Deal

Four months after two Endocyte drug candidates stumbled in early-stage studies, sparking a corporate shakeup, the company has signed a deal landing an experimental prostate cancer treatment that it sa...

Endocyte licenses radioligand prostate cancer therapy from ABX GMBH

Endocyte Inc. received exclusive global rights to the radioligand therapeutic PSMA617 (177LuPSMA617) from ABX GMBH.

STAT Plus: How a whole lot of hype sent Endocyte’s stock soaring for no good reason

Endocyte's stock price has quadrupled since it licensed an experimental prostate cancer drug. Problem is, the drug is not likely to work — or sell — well.

Endocyte announces exclusive worldwide license of PSMA-targeted radioligand therapy for development in prostate cancer

Endocyte has announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH.

Endocyte bounces back with late-stage prostate cancer deal

Endocyte saw its share price take off yesterday after it acquired rights to a promising late-stage cancer therapy. The company’s stock rose more than 150% in a day, with investors sensing that the ...

Endocyte Refocuses Development on Prostate Cancer Radioligand Therapeutic

Endocyte said today it has licensed ABX’s radioligand therapeutic (RLT) candidate PSMA-617 in a deal that could generate up to $177 million-plus for the German nuclear medicine company, adding that ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Extension Study of EC145 for Subjects Enrolled in a Previous Study With EC145

This extension protocol is for those subjects that have completed the allowed duration of participation in an Endocyte-sponsored clinical trial of EC145 and have continuing evidence of cli...

Companies [4 Associated Companies listed on BioPortfolio]

Endocyte Incorporated

Endocyte, Inc is a biotechnology company focused on vitamin based drug targeting and delivery systems. Vitamins are essential components for specific biological cellular functions. Endocyte's mission ...

Endocyte, Inc.

Endocyte is a privately held biotechnology company with headquarters in the Purdue Research Park of West Lafayette, IN. Based on the applications of Endocyte’s advanced propr...

Endocyte

Endocyte is developing a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are usually toxic to normal h...

Merck and Endocyte

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines,...

More Information about "Endocyte, Inc." on BioPortfolio

We have published hundreds of Endocyte, Inc. news stories on BioPortfolio along with dozens of Endocyte, Inc. Clinical Trials and PubMed Articles about Endocyte, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Endocyte, Inc. Companies in our database. You can also find out about relevant Endocyte, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Corporate Database Quicklinks



Searches Linking to this Company Record